14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AAPG vs IONS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 50.2/100 (HOLD) at $13.43 (9.7x Forward P/E, -219.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin).
Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs IONS. Trailing 12-month operating profitability (AAPG -219.5% vs IONS -58.8%) and valuation multiples (AAPG 9.7x vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment61.8% of Rev ($593M)
90D Engineering Disclosures0 Published
Investor FAQ AAPG vs IONS Key Questions & Quantitative Answers
As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 50.2/100 (HOLD) at $13.43 (9.7x Forward P/E, -219.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin). Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IONS leads the Growth & Scale pillar: AAPG posts +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). On trailing 12-month operating scale, AAPG generates $643M in USD-normalized revenue versus $960M for IONS. In operating R&D and SG&A reinvestment, AAPG deploys N/A (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.
AAPG screens cheaper on headline valuation multiples. AAPG trades at 9.7x Forward P/E, 9.7x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (unreported EBITDA margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPG (-236.6% ROE) versus IONS (-108.0% ROE) capital efficiency.
In options market volatility and institutional positioning, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.31β · 69% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.